Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: HPB (Oxford). 2020 Sep 17;23(4):551–559. doi: 10.1016/j.hpb.2020.08.013

Table 3.

Multivariable Analysis for All Patients with PHLF

PHLF
n (%)
Adjusted Odds Ratio
(95% CI)
P value
Age, mean (SD)* 64.9 (11.2) 1.21 (1.05 - 1.38) 0.008
Sex
 Male 132 (3.9) 1.00 (REF) -
 Female 55 (1.5) 0.62 (0.45 - 0.85) 0.003
ASA Class
 I/II 21 (1.1) 1.00 (REF) -
 III/IV/V 166 (3.3) 1.85 (1.10 - 3.11) 0.021
Ascites 9 (18.8) 4.94 (2.45 - 9.94) < 0.001
Bleeding disorder 20 (8.0) 2.10 (1.18 - 3.44) 0.011
Elevated SGOT > 40 82 (6.7) 2.11 (1.53 - 2.92) < 0.001
Surgical Pathology
 Benign 19 (1.0) 1.00 (REF) -
 Primary Hepatobiliary 120 (5.5) 2.14 (1.29 - 3.54) 0.003
 Secondary/Unknown 48 (1.7) 1.09 (0.74 - 1.59) 0.677
Operative Time (hours), mean (SD)** 4.4 (2.0) 1.17 (1.09 - 1.26) < 0.001
Surgical Approach
 Minimally Invasive 25 (1.2) 1.00 (REF) -
 Open/Other 162 (3.3) 1.98 (1.33 - 2.94) < 0.001
Liver Texture
 Normal/Not documented 97 (1.8) 1.00 (REF) -
 Cirrhotic/Congested/Fatty/Fibrotic 90 (5.3) 1.92 (1.36 - 2.72) < 0.001
Pringle Maneuver 59 (4.6) 1.60 (0.91 - 2.82) 0.100
Surgical Drain 113 (3.9) 1.57 (0.95 - 2.60) 0.078
*

OR reported for each additional 10 years

**

OR reported for each additional hour

Abbreviations: PHLF, post-hepatectomy liver failure; SD, standard deviation; ASA, American Society of Anesthesiologists Classification; SGOT, aspartate transaminase; MIS, minimally invasive surgery